AFFINITY 3 MANAGEMENT, LLC

The individuals responsible for investment decisions at Affinity 3 Management have not been publicly identified. The firm does not maintain a website, LinkedIn profile, or public filings that list principals or investment officers. This lack of transparency is consistent with a family office that intentionally avoids public disclosure.

Given the firm's opaque structure, the specific process for sourcing deal flow is unknown. The firm likely relies on family connections, existing professional networks, and co-investment relationships. The known positions in Fortress Biotech and Relmada Therapeutics suggest some exposure to healthcare and biotech deals.

Available records indicate Affinity 3 Management is structured as a single family office. The firm's name and legal registration as an LLC in Delaware suggest it serves one family's capital. There is no evidence of third-party capital, fund structures, or any venture-firm operations.

The firm's known holdings include stakes in publicly traded companies like Fortress Biotech and Relmada Therapeutics, indicating an ability to invest in both publicly-listed equities and potentially private companies. The exact stage preference—whether early-stage, growth, or public markets—is not publicly specified.

The firm has not publicly disclosed any sectors it avoids. The limited public holdings point to healthcare and biotechnology, but there is no confirmed list of excluded industries.

There is no public information indicating that Affinity 3 Management maintains a separate philanthropic foundation or charitable arm. The firm appears to operate solely as a family investment vehicle, with no disclosed affiliated charitable entities.

The firm's holdings are limited to direct stakes in public companies, and there is no public record of co-investments alongside external general partners. The available data suggests a preference for direct equity holdings rather than fund commitments or co-investment arrangements.